KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Shares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

AbCellera Biologics (ABCL) EBITDA (2020 - 2023)

AbCellera Biologics' EBITDA history spans 4 years, with the latest figure at -$47.4 million for Q4 2023.

  • For the quarter ending Q4 2023, EBITDA fell 55.1% year-over-year to -$47.4 million, compared with a TTM value of -$146.7 million through Dec 2023, down 193.55%, and an annual FY2024 reading of -$165.5 million, down 12.8% over the prior year.
  • EBITDA for Q4 2023 was -$47.4 million at AbCellera Biologics, down from -$28.2 million in the prior quarter.
  • The five-year high for EBITDA was $169.1 million in Q1 2022, with the low at -$47.4 million in Q4 2023.
  • Average EBITDA over 4 years is $17.7 million, with a median of -$2.4 million recorded in 2020.
  • Year-over-year, EBITDA soared 5624.08% in 2021 and then plummeted 3991.23% in 2022.
  • Tracing ABCL's EBITDA over 4 years: stood at $117.0 million in 2020, then crashed by 49.07% to $59.6 million in 2021, then crashed by 151.3% to -$30.6 million in 2022, then plummeted by 55.1% to -$47.4 million in 2023.
  • Per Business Quant, the three most recent readings for ABCL's EBITDA are -$47.4 million (Q4 2023), -$28.2 million (Q3 2023), and -$30.4 million (Q2 2023).